Evaluating Glutamatergic Transmission in Schizophrenia

Carol A. Tamminga, Adrienne C. Lahti, Deborah R. Medoff, Xue Min Gao, Henry H. Holcomb

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume1003
DOIs
StatePublished - Nov 2003

Fingerprint

Functional Neuroimaging
Dizocilpine Maleate
Ketamine
Glutamic Acid
Brain
Schizophrenia
Animals
Chemical activation
Pharmacology
Imaging techniques
Pharmaceutical Preparations
Drugs
Activation
Brain Imaging

Keywords

  • Glutamatergic system
  • Ketamine
  • MK-801
  • Molecular targets
  • PCP
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Evaluating Glutamatergic Transmission in Schizophrenia. / Tamminga, Carol A.; Lahti, Adrienne C.; Medoff, Deborah R.; Gao, Xue Min; Holcomb, Henry H.

In: Annals of the New York Academy of Sciences, Vol. 1003, 11.2003, p. 113-118.

Research output: Contribution to journalArticle

Tamminga, Carol A. ; Lahti, Adrienne C. ; Medoff, Deborah R. ; Gao, Xue Min ; Holcomb, Henry H. / Evaluating Glutamatergic Transmission in Schizophrenia. In: Annals of the New York Academy of Sciences. 2003 ; Vol. 1003. pp. 113-118.
@article{9b2595bdd95f4138b578f3581ef2c78f,
title = "Evaluating Glutamatergic Transmission in Schizophrenia",
abstract = "Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.",
keywords = "Glutamatergic system, Ketamine, MK-801, Molecular targets, PCP, Psychosis, Schizophrenia",
author = "Tamminga, {Carol A.} and Lahti, {Adrienne C.} and Medoff, {Deborah R.} and Gao, {Xue Min} and Holcomb, {Henry H.}",
year = "2003",
month = "11",
doi = "10.1196/annals.1300.062",
language = "English (US)",
volume = "1003",
pages = "113--118",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Evaluating Glutamatergic Transmission in Schizophrenia

AU - Tamminga, Carol A.

AU - Lahti, Adrienne C.

AU - Medoff, Deborah R.

AU - Gao, Xue Min

AU - Holcomb, Henry H.

PY - 2003/11

Y1 - 2003/11

N2 - Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.

AB - Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.

KW - Glutamatergic system

KW - Ketamine

KW - MK-801

KW - Molecular targets

KW - PCP

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0347722467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347722467&partnerID=8YFLogxK

U2 - 10.1196/annals.1300.062

DO - 10.1196/annals.1300.062

M3 - Article

C2 - 14684439

AN - SCOPUS:0347722467

VL - 1003

SP - 113

EP - 118

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -